Powell delivers early fireworks to markets Powell delivers early fireworks to markets Powell delivers early fireworks to markets

Powell delivers early fireworks to markets

Equities 4 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  Yesterday's US inflation report did nothing to stop the strong sentiment in equities setting markets up for a potential disappointment at tonight's FOMC press conference. US core services inflation has accelerated the past three months which might have spooked the Fed into doubling down on its message of higher for longer. If this is the case then equities will be great disappointed. After the US market close, Adobe will report earnings and investors are likely demanding that the company's generative AI product Firefly begin to move the needle on growth. If not, then it will be increasingly difficult to justify the current valuation.

The Fed buys into market narrative

Last night the FOMC bought into the recent market narrative pricing in rate cuts next year as inflation continues to cool, although in the short term US core services inflation remains high, forecasting three rate cuts next year compared to five cuts priced by the market (see price chart of SOFR Dec 2024 below). The message extended the rally in equities pushing Nasdaq 100 futures to a new all-time high on the close and the move has extended today with the index futures trading around the 16,850 level. It is not unrealistic to think that the S&P 500 could hit 5,000 in a complete melt-up scenario by yearend.

From a strategic perspective the Fed is happy with its policy forecast spread to market pricing on rate cuts as any error will force the market to correct first creating a buffer for policymakers. As such the Fed will likely continue to update its forecasts for rate cuts in tandem with market pricing keeping a certain spread in place with two rate cuts being the current spread. Some say that the market is getting too aggressive in its pricing but history is on the side of markets because when a rate cycle begins the policy rate trajectory often accelerates faster than most anticipate. This could easily happen again.

The logical narrative in the market is that the policy rate repricing drives the market through valuation expansion, but as our chart below shows there has been little logical connection between the market’s pricing of Fed policy rate Dec 2024 and the forward equity valuation of the S&P 500. In other words, if the repricing matters for equities is a local phenomenon and not a generalized dynamic. As we have been writing for quite some time, the market’s logic is this. As long as the policy rate is only projected to fall less than 200 bps then the interpretation is a soft landing meaning lowering discount rate on cash flow with stable nominal growth of 4-6%. This will support the positive momentum in equities, but if the policy rate pricing exceed the 200 bps then the equity market will begin realising that policy rate cuts are suddenly an expression of an incoming recession and then the market dynamic will flip upside down.

SOFR Dec 2024 futures | Source: Saxo
Nasdaq 100 futures | Source: Saxo

ECB cools market pricing on rate cuts

Today’s ECB rate decision was no surprise in the sense of policy rates remaining unchanged but the central bank reiterated its higher for longer message despite lowering its inflation forecasts for next year on core inflation to 2.7% from previously 2.9% in addition to lowering its Eurozone GDP forecast for 2024 to 0.8% from previously 1%. These new forecasts underscore the fragility of the Eurozone economy but also supports rate cuts next year although the market is today lowering the change in policy rate a bit. However, if the economy continues to be slow paced the market will likely resume its pricing of more aggressive rate cuts for next year. The current ECB policy rate pricing in Dec 2024 is 2.36% vs 4% deposit facility rate.

Pfizer shares are down 45% in 2023 as 2024 outlook disappoints

A terrible year for Pfizer got worse yesterday with shares falling another 7% extending this year’s decline to 45.6% as the company updated the market on its 2024 outlook. Pfizer is guiding revenue of $58.5-61.5bn vs est. $62.9bn. In addition, the company said it expects $4bn in cost savings next year, but the market was clearly weighing growth over profitability in the update. Pfizer’s lower market value has pushed its equity valuation to around 6.2% on the FY24 free cash flow yield and 7x on FY24 EV/EBITDA which is a significant discount to the S&P 500 which valued at 12x on EV/EBITDA. In that sense, Pfizer is now truly a value company, but it has likely also become the case for the patient investor as there are no near-term catalysts that can change sentiment except for falling bond yields.

Pfizer share price | Source: Saxo

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.